ThermoGenesis Holdings, Inc. · OTC:THMO

ThermoGenesis — Merger or Acquisition (July 2013)

30 slides from ThermoGenesis's merger presentation, Jul 17, 2013

  1. Slide 1: The Merger of ThermoGenesis & TotipotentRX

    Corporate Presentation The Merger of ThermoGenesis & TotipotentRX July 2013 Exhibit 99.3 Filed by: ThermoGenesis Corp. Pursuant to Rule 425 under the Securities Act of 1933 Subject Company: ThermoGenesis Corp. Commission File No.: 333-82900

  2. Slide 2: Forward Looking Statement

    Cesca TM Therapeutics Forward Looking Statement ThermoGenesis Corp. Web site: http://www.thermogenesis.com Contact: Investor Relations +1-916-858-5107, or ir@thermogenesis.com

  3. Slide 3: Launches only integrated regenerative medicine company

    Cesca Therapeutics Launches only integrated regenerative medicine company

  4. Slide 4: TotipotentRX snapshot

    Cesca Therapeutics TotipotentRX snapshot • Developing cellular therapies for vascular, orthopedic and neurological diseases • Core capabilities in development and clinical testing of cellular therapies • Pipeline of 10 clinical stage therapies THERAPEUTICS DEVICES CLINICAL SERVICES

  5. Slide 5: ThermoGenesis snapshot

    Automated Point-of-Care/ Lab-based cGMP Closed Systems Scalable Cesca Therapeutics ThermoGenesis snapshot (Nasdaq: KOOL) • Leading designer and supplier of clinical technologies for processing, storage and administration of stem cells • Core capabilities include quality innovation, design IP, commer

  6. Slide 6: Regenerative Medicine's Future

    Regenerative Medicine’s Future Macro drivers • Global Trends in Healthcare − Aging population, rapidly rising costs − Medical reimbursement; pay for performance − Pharma: Ø Patent expirations, empty pipelines Ø Not curative, treats symptoms • Regenerative Medicine − Curative; targets root cause of d

  7. Slide 7: Industry presence accelerating

    Industry presence accelerating Healthcare Market Macro drivers • Regenerative medicine gains industry’s eye − Industry clinical trial sponsors: ü 2007: <1% ü 2010: 5% ü 2012: 20% • Academic cell evolution; From embryonic, to allogeneic, to autologous: − CIRM has begun funding autologous trials again

  8. Slide 8: Autologous Therapy Today

    Autologous Therapy Today Current regenerative medicine POC practice

  9. Slide 9: The autologous cell therapy solution

    Cesca Therapeutics The autologous cell therapy solution • Patient friendly • Physician friendly • Fast, at-the-bedside • Effective • In the regulatory “sweet spot” • Commercially viable Consistent cell compositions cGMP compliant protocols Clinical data

  10. Slide 10: Commercialization Advantage

    Cesca Commercialization Advantage The first commercially viable autologous cell therapy

  11. Slide 11: Cellwerks: Our Unique Development Process

    Cesca Cellwerks SM Our Unique Development Process • Uniquely integrated development - Chemistry, cellularity and quality - Controlled, consistent delivery - 550 patients treated across eight clinical indications (Toti)

  12. Slide 12: Surgwerks: Indication specific, proprietary product suite

    Cesca Surgwerks TM Indication specific, proprietary product suite

  13. Slide 13: Sustainable differentiation

    Cesca Surgwerks TM Sustainable differentiation • Developed at the point-of-care, over 20,000 patients treated through ThermoGenesis • Clinically validated, proprietary clinical protocols & method patents • Proprietary, smart platforms (device and algorithm patents) • Proprietary cell formulations ad

  14. Slide 14: In the Regulatory "Sweet Spot"

    In the Regulatory “Sweet Spot” Lower risk = speed to market

  15. Slide 15: Proprietary Cell Formulations

    Source Material Clinical Indication Harvest Hct (%) MNC recovery (%) Monocyte recovery Platelet recovery (%) PB Chronic Dermal Wound ≤ 25% > 80% > 85% > 85% PB Chronic Dermal Wound ≤ 10% > 80% > 85% > 85% PB Soft Tissue ≤ 3% > 50% > 80% > 85% PB Soft Tissue ≤ 2% > 50% > 80% > 85% BM Cardiac & CLI ≤

  16. Slide 16: Cesca Pilot Trial Experience

    Specialty Indication Trial Completion Orthopedics OA 50 Patients Pilot Completed Non Union 30 Patients Pilot Completed 19 Patients Phase 1 Completed Avascular Necrosis 10 Patients Pilot Completed Cardiovascular AMI 30 Patient Phase 1b Underway Stroke 15 Patient Phase 1a Reg Review CLI 15 Patient Pha

  17. Slide 17: High Impact Clinical Results: Major Revascularization

    Major Revascularization High Impact Clinical Results Compelling early vascular results • N=17 patients • All patients “no option” and 24 hours from leg amputation • 88.9% of gangrene sores improved • Major Amputation Free Rate post SurgWerks ™ Therapy = 85.7% • Minor Amputation Free Rate Post SurgWe

  18. Slide 18: High Impact Clinical Results: Long Bone Fusion Non-Union Fractures

    Long Bone Fusion Non-Union Fractures • N=19 patients • All patients failed traditional surgical fixation • 71% union rate in 18 weeks post SurgWerks ™ treatment – No SAEs/AES – 2 patients lost to F/U High Impact Clinical Results Compelling early orthopedic results Accepted for publication: 2012 Inte

  19. Slide 19: Clinical Pipeline: Blockbuster drug candidates

    KEY CESCA CRO ADVANTAGES − US FDA accepts foreign trials − Better control of trial management − 1/5th the cost of US/EU Patient related Clinical Trials costs − Speed to completion Clinical Pipeline Blockbuster drug candidates

  20. Slide 20: Our Fortis Partnership

    Our Fortis Partnership CRO embedded in New Delhi facility • Cesca is exclusive regenerative medicine provider to Fortis – 72 hospitals (6 countries) – 10,000 inpatient beds – 15,000 outpatients per day – Competent clinical research staff – 2x as many sites as Kaiser • Physician/patient access • Worl

  21. Slide 21: Co-Development and Marketing Prospects

    VASCULAR CONDITIONS ORTHOPEDIC CONDITIONS AMI CLI STROKE NON HEALING ULCERS SPINE OA NON UNION FRACTURES AVN Cook X X X Sanofi X X Shire X X X Pfizer X X X Medtronic X X X X X Abbott X X J&J X X X X X X X Terumo X X X X Baxter X X Amgen X Stryker X X X X Biomet X X X X Arthrex X X X X TOTAL PROSPECT

  22. Slide 22: Unlocking Intrinsic Value of Base Business

    Unlocking Intrinsic Value of Base Business Expanding clinical uses for cord blood • Accelerate Cord Blood Organic Revenue − Leverage first mover position in Asia − Take competitive share in Europe and the Americas − Introduce advanced AXP upgrades, new products, and support • Expand Practice of Medi

  23. Slide 23: Leveraging Cord blood

    Leveraging Cord blood Global automated processing leader Exclusive automated cord blood processing device provider to CCBC Exclusive AXP distributor in China and several Southeast Asian countries Strong foundation in Golden Meditech and Cesca Research Bank allows us to capitalize on the Asia growth

  24. Slide 24: Overview of Key Milestones

    Overview of Key Milestones Substantial near term clinical value drivers • 2013 − Cardiac Patient Ph1b Enrollment Commences • 2014 − Clinical Trial Approval (NHU IRB) − Clinical Trial Approval (OA IRB) − US Investigational New Drug Granted (CLI Ph1/2) − Cardiac Patient Ph1b Enrollment Completed − Ph1

  25. Slide 25: Value Capture of Cesca Transformation

    Value Capture of Cesca Transformation Revenue multiple expansion catalyst CESCA THERAPEUTICS PEER GROUP Cytori, Aastrom, Athersys, Neostem, Cytomedix, Mesoblast, BioTime, Osiris, Harvest

  26. Slide 26: Cesca Growth Capital Investment

    Category Growth Capital • Clinical Development & Regulatory Initiatives - AMI, Stroke, OA, NHU - CLI, Spine, NUF, AVN $15M • Product Commercialization - Cord Blood (Distribution, Launches) - Clinical Commercial Zones $2M • Device Development & General Capital Req’s - Diagnostics Devices $3M Total $2

  27. Slide 27: Senior Leadership

    Cesca Senior Leadership Seasoned industry executives: Significant Insider ownership Matthew T. Plavan CHIEF EXECUTIVE OFFICER, BOD § COO ’08-’10 (3yrs), CFO ‘05-’13 (8yrs), & CFO for two venture-backed start-ups (5 yrs) § Vice-President of Finance & Gen. Mgr McKesson (7yrs) & Ernst & Young (6yrs) Ke

  28. Slide 28: Investment Highlights

    Cesca Investment Highlights Uniquely positioned to lead in regenerative medicine • Regenerative medicine is a major element of our future healthcare system • Our integrated device, point-of-care services and Indian CRO business is a capital efficient, regulatory compliant model able to expedite new

  29. Slide 29: Additional Information

    Cesca Therapeutics Additional Information • Non-Solicitation − This presentation and the information contained herein shall not constitute an offer to sell, buy or exchange or the solicitation of an offer to sell, buy or exchange any securities, nor shall there be any sale, purchase or exchange of s

  30. Slide 30: Thank you

    Thank you

Thermogenesis — Merger or Acquisition (July 2013) on 6ix